Molecular targeted treatment and radiation therapy for rectal cancer

Strahlentherapie und Onkologie

Volumn 185, Issue 6, 2009, Pages 371-378

  Marquardt, Friederike ^a   Rödel, Franz ^a   Capalbo, Gianni ^a   Weiss, Christian ^a   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Bevacizumab; Cetuximab; Chemoradiotherapy; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; UFT; VASCULOTROPIN INHIBITOR;

ACNE; ANUS DISEASE; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; COLITIS; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEART INFARCTION; HUMAN; HYPERTENSION; INTESTINAL BLEEDING; INTESTINE PERFORATION; ISCHEMIA; ISCHEMIC COLITIS; LEUKOPENIA; LOADING DRUG DOSE; LUNG EMBOLISM; MUCOSA INFLAMMATION; NEUTROPENIA; ONCOGENE K RAS; PAIN; PREOPERATIVE TREATMENT; RADIOSENSITIZATION; RECTUM CANCER; RECTUM PERFORATION; SEPSIS; SKIN DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; HUMANS; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67149086939     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-009-1936-5     Document Type: Article

References (47)

1. D. Azria F. Bibeau N. Barbier 2005 Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer BMC Cancer 5 62
2. C. Bengala S. Bettelli F. Bertolini 2008 Predictive value of EGFR gene copy number and K-ras mutation for pathological response to preoperative cetuximab, 5FU, and radiation therapy in locally advanced rectal cancer (LARC) J Clin Oncol 26 4125
3. F. Bertolini C. Bengala L. Losi 2007 Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy Int J Radiat Oncol Biol Phys 68 1455 61
4. Bertolini F, Zironi S, Malavasi N, et al. Phase II study of pre-operative cetuximab, fluorouracil (5FU), and radiotherapy (RT) in patients with rectal cancer (RC). ASCO Gastrointestinal Cancers Symposium, Orlando, FL, USA, 19.1.2007.abstract 308.
5. J.A. Bonner P.M. Harari J. Giralt 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 78
6. J.F. Bosset L. Collette G. Calais 2006 Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 355 1114 23
7. E.C. Cabebe T. Kuo A. Koong 2008 Phase I trial of preoperative cetuximab in combination with oxaliplatin, capecitabine, and radiation therapy for locally advanced rectal cancer J Clin Oncol 26 15019
8. S. Cascinu F. Graziano V. Catalano 2002 An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation Br J Cancer 86 744 9
9. K.Y. Chung B. Minsky D. Schrag 2006 Phase I trial of preoperative cetuximab with concurrent continuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer J Clin Oncol 24 3560
10. C.H. Crane C.B. Eng W. Feig 2008 Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer J Clin Oncol 26 4091
11. D. Cunningham Y. Humblet S. Siena 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 45
12. B.G. Czito J.C. Bendell C.G. Willett 2007 Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results Int J Radiat Oncol Biol Phys 68 472 8
13. W. De Roock H. Piessevaux J. De Schutter 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 15
14. T.A. DiPetrillo V. Pricolo W.M. Sikov 2008 Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer J Clin Oncol 26 15041
15. J.P. Gerard T. Conroy F. Bonnetain 2006 Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 24 4620 5
16. J. Giralt M. de las Heras L. Cerezo 2005 The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis Radiother Oncol 74 101 8
17. J. Giralt A. Eraso M. Armengol 2002 Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy Int J Radiat Oncol Biol Phys 54 1460 5
18. J. Giralt B. Navalpotro E. Hermosilla 2006 Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy Oncology 71 312 9
19. D.H. Gorski M.A. Beckett N.T. Jaskowiak 1999 Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 3374 8
20. K. Haustermans S. Roels J. Verstraete 2007 Adaptive RT in rectal cancer: superior to 3D-CRT? A simple question, a complex answer Strahlenther Onkol 183 Special Issue 2:21 3
21. R.D. Hofheinz K. Horisberger C. Woernle 2006 Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer Int J Radiat Oncol Biol Phys 66 1384 90
22. H. Hurwitz L. Fehrenbacher W. Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 42
23. J.S. Kim J.M. Kim S. Li 2006 Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy Int J Radiat Oncol Biol Phys 66 195 200 (Pubitemid 44175651)
24. R. Kopp E. Rothbauer E. Mueller 2003 Reduced survival of rectal cancer patients with increased tumor epidermal growth factor receptor levels Dis Colon Rectum 46 1391 9
25. C.G. Lee M. Heijn E. di Tomaso 2000 Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 5565 70
26. S. Li J.S. Kim J.M. Kim 2006 Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation Int J Radiat Oncol Biol Phys 65 705 12
27. F. Lordick H. Geinitz J. Theisen 2006 Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases Int J Radiat Oncol Biol Phys 64 1295 8
28. J.H. Machiels A. Debucquoy O. Gevaert 2008 Prediction of pathological response to preoperative chemoradiotherapy with cetuximab in rectal cancer J Clin Oncol 26 4095
29. J.P. Machiels C. Sempoux P. Scalliet 2007 Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer Ann Oncol 18 738 44
30. Marijnen CA. Preoperative chemoradiotherapy regimen with capecitabine and bevacizumab in locally advanced rectal cancer: a feasibility study of the Dutch Colorectal Cancer Group (DCCG). Proc Am Soc Clin Oncol 2008;27:abstract 15040.
31. V. Milani M. Pazos R.D. Issels 2008 Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer Strahlenther Onkol 184 163 8
32. L. Milas K. Mason N. Hunter 2000 In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 701 8
33. N. Moosmann V. Heinemann 2008 Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer Expert Rev Anticancer Ther 8 319 29
34. M.P. Morelli T. Cascone T. Troiani 2005 Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors Ann Oncol 16 Suppl4 iv61 8
35. F.V. Negri N. Campanini R. Camisa 2008 Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy Br J Cancer 98 143 7
36. F. Paris Z. Fuks A. Kang 2001 Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice Science 293 293 7
37. W. Rhomberg J. Hammer F. Sedlmayer 2007 Irradiation with and without razoxane in the treatment of incompletely resected or inoperable recurrent rectal cancer. Results of a small randomized multicenter study Strahlenther Onkol 183 380 4
38. C. Rödel D. Arnold M. Hipp 2008 Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer Int J Radiat Oncol Biol Phys 70 1081 6
39. C. Rödel R. Sauer 2007 Integration of novel agents into combined-modality treatment for rectal cancer patients Strahlenther Onkol 183 227 35
40. R. Sauer H. Becker W. Hohenberger 2004 Preoperative versus postoperative chemoradiotherapy for rectal cancer N Engl J Med 351 1731 40
41. K.L. Spindler J.N. Nielsen J. Lindebjerg 2006 Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region Int J Radiat Oncol Biol Phys 66 500 4
42. V. Valentini A. De Paoli M.A. Gambacorta 2008 Infusional 5-fluorouracil and ZD1839 (fefitinib-IRESSA) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II trial (1839IL/0092) Int J Radiat Oncol Biol Phys 72 644 9
43. C.G. Willett Y. Boucher E. di Tomaso 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 7
44. C.G. Willett Y. Boucher D.G. Duda 2005 Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients J Clin Oncol 23 8136 9
45. C.G. Willett D.G. Duda L. Xu 2008 Correlation of blood and physiologic markers with effect of bevacizumab (BV) with chemoradiation therapy in rectal cancer (RC) J Clin Oncol 26 4096
46. R. Wollman J. Yahalom R. Maxy 1994 Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro Int J Radiat Oncol Biol Phys 30 91 8
47. I. Zlobec T. Vuong C.C. Compton 2008 Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy Br J Cancer 98 450 6